

Imaging Contrast Policy Updates

Imaging recently had contrast policies updated-effective 6/1/25

- ❑ **1PC.RAD.0008-** Information updated to allow providers the ability to shorten premedication protocols in emergent situations for patients with moderate allergies.
- ❑ **1PC.RAD.0523-** Gadolinium is now broken into 3 groups. Group II agents do not require eGFR testing prior to the procedure. Mission Health only uses Group II agents at this time.
- ❑ Female patients, for contrasted MRI studies, are screened for pregnancy. If the patient is pregnant, the radiologist, ordering provider and patient must have conversation and a legal consent must be approved to proceed.
- ❑ **1PC.RAD.0524-** Iodinated contrast screening requirements no longer require screening for patients 60 and over or with hypertension. New screening requirements include thyroid conditions.
- ❑ Pharmacy verification for contrast is for documentation purposes only. The technologist is responsible for screening the patient appropriately prior to contrast administration.
- ❑ Metformin is broken into Category I and Category II for iodinated contrast studies. Guidelines have been updated to no longer require discontinuation for a period of time following contrast administration if the eGFR is $> 30 \text{ ml/min/1.73m}^2$. Guidelines are provided for patients under 30.
- ❑ **1PC.RAD.0527** is a NEW policy regarding IV access routes for contrast administration. This policy contains information regarding EJ and IO routes.